Drug Profile
QL 007
Alternative Names: QL007Latest Information Update: 28 Sep 2022
Price :
$50
*
At a glance
- Originator Qilu Pharmaceutical
- Class Antivirals
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Hepatitis B
Most Recent Events
- 28 Sep 2022 No development reported - Phase-II for Hepatitis B (Combination therapy, Treatment-experienced) in China (PO)
- 28 Sep 2022 No development reported - Phase-II for Hepatitis B (Combination therapy, Treatment-naive) in China (PO)
- 28 Sep 2020 No recent reports of development identified for phase-I development in Hepatitis-B in New Zealand (PO, Tablet)